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Objectives: To evaluate rhythm control up to two years after atrial fibrillation (AF) ablation and its
relation to reported symptoms.
Background: The implantable loop recorder (ILR) continuously records the electrocardiogram (ECG),
has an automatic AF detection algorithm, and has a possibility for patients to activate an ECG recording
during symptoms.
Methods: Fifty-seven patients (mean age 57 ± 9 years, 60% male, 88% paroxysmal AF) underwent AF
ablation following ILR implantation. Device data were downloaded at the ablation and three, six, 12, 18,
and 24 months after ablation.
Results: Fifty-four patients completed the two-year follow-up. Thirteen (24%) patients had no AF
episodes detected by ILR during follow-up. Ten of 41 patients (24%) with AF recurrence were only
detected by ILR and AF recurrences were detected earlier by ILR (P < 0.001). The median AF burden in
patients with AF recurrence was 5.7% (interquartile range 0.4–14.4) and was even lower in patients with
AF only detected by ILR (P = 0.001). Forty-eight % of the patients indicated symptoms via the patient
activator but 33% of those recordings were not due to AF. Early AF recurrence (within 3 months) was
highly associated with later AF recurrence (P< 0.001). AF burden>0.5% and longest AF episode>6 hours
before the ablation were independent predictors of AF recurrence during intermittent but not continuous
monitoring.
Conclusions: After AF ablation, the AF burden was low throughout the 24 months follow-up.
Nevertheless, symptoms were commonly indicated but one-third of patient-activated recordings did not
show AF. Continuous monitoring was superior to intermittent follow-up in detecting AF episodes and
assessing the AF burden. (PACE 2016; 39:914–925)
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Introduction
Current guidelines recommend catheter abla-
tion of atrial fibrillation (AF) after failure of at
least one antiarrhythmic drug (AAD) but can be
considered as initial therapy in selected cases.1
Success rates after AF ablation are currently based
on symptoms, intermittent standard electrocar-
diogram (ECG) recordings, and ambulatory long-
term monitoring. However, asymptomatic AF is
common,2 and the proportion of recurrent asymp-
tomatic compared to symptomatic AF episodes
increases after ablation.3 Based on these current
follow-up strategies, the success rates of AF
ablation might be overestimated, and continuous
long-term ECG monitoring for detection of AF with
a possibility of symptom versus ECG correlation
may provide more accurate information on rhythm
status after ablation.
©2016 The Authors. Pacing and Clinical Electrophysiology published by Wiley Periodicals, Inc.
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Continuous monitoring using cardiac im-
plantable electronic devices found the duration of
AF episodes to be associated with an increased
risk of stroke.4–7 Furthermore, Boriani et al.
showed that the stroke risk was associated with the
duration of the AF episodes in combination with
CHADS2 or CHA2DS2-VASc scores.
8 AF detection
during continuous rhythm monitoring with a
subcutaneously implanted loop recorder (ILR) was
validated in the XPECT study.9 ILRs have since
been used in clinical studies for detection of AF
after ablation with follow-up periods of up to 12
months.10,11
The aim of this study was to evaluate the
rhythm control during the first two years after
AF ablation, assessed by continuous monitoring
using ILRs and intermittent monitoring, and its
relationship with reported symptoms.
Materials and Methods
Patients who were scheduled for AF ablation
between April 2009 and January 2013 at O¨rebro
University Hospital, Sweden, and Odense Univer-
sity Hospital, Denmark, were eligible for inclusion
in this prospective two-center study. All patients
had symptomatic paroxysmal or persistent AF
and provided written informed consent. The
study protocol was approved by the appropriate
ethical boards and was in compliance with the
Declaration of Helsinki.
Device Characteristics, Implant Procedure,
and Interpretation of AF Episodes
At least two weeks before the AF ablation, all
patients received an ILR (Reveal R© XT, Medtronic
Inc., Minneapolis, MN, USA), which was im-
planted subcutaneously in the left parasternal
area. The device has a battery longevity of up to
three years. It automatically classifies and saves
30-s recordings of predefined arrhythmias (atrial
tachycardia, AF, bradycardia, asystole, or fast
ventricular tachyarrhythmia). The AF detection
algorithm uses irregularity and incoherence in
R-R intervals to identify and classify patterns
in the ventricular conduction. The R-R intervals
are analyzed within two-minute periods, and the
difference in duration between consecutive R-R
intervals (R-R) is calculated. The variability of
these R-R intervals is subsequently calculated
in a way similar to constructing a Lorenz
plot.12 When R-R intervals within the two-minute
interval show a certain pattern of uncorrelated
irregularity, the rhythm in this interval is classified
as AF.9 All patients were equipped with the Pa-
tient Assistant activator that enables the patient to
save and store ECG in the ILR when experiencing
symptoms of AF. The episode log shows up to
30 automatically detected AF episodes and up
to 10 patient-activated episodes. In total, 49.5
minutes of ECG could be stored. When the memory
is full, the first stored episode is overwritten
by the latest episode. The ILR was interrogated
at each outpatient visit. The episode log and
recorded ECGs were all visually adjudicated by
two experienced cardiologists (A.Br and A.Bj). The
AF burden was calculated and reported based on
all adjudicated AF episodes.
Catheter Ablation Procedure
The procedure was performed on
uninterrupted oral anticoagulation with warfarin
within the therapeutic international normalized
ratio interval at least four weeks before ablation.
Real-time 3D electroanatomic mapping was
performed (CARTO Merge, Biosense Webster,
Diamond Bar, CA, USA). Circumferential lines
were produced around each pair of pulmonary
vein (PV) ostia. The end point was the absence
of PV signals for at least 15 minutes during sinus
rhythm (SR). Direct current cardioversion was
performed as needed. After ablation, all patients
were observed on telemetry monitoring for 24–48
hours. AADs and warfarin were continued for
three to six months after the ablation and then
reevaluated. Withdrawal of AADs was guided
by symptoms and intermittent ECG monitoring
rather than the actual AF burden. Anticoagulation
therapy was based on the CHA2DS2-VASc score
regardless of arrhythmia status.
Follow-Up
The ILR was interrogated at ablation and
during scheduled visits three, six, 12, 18, and
24 months after ablation or during unscheduled
visits for presumed AF symptoms. A continuous
Holter monitoring (SpaceLabs Healthcare, Sno-
qualmie, WA, USA) or a continuous external
loop monitoring (R.TEST Evolution 3, NOVACOR,
Rueil-Malmaison, France) for 48–96 hours was
performed at each visit. A 12-lead ECG was
recorded at each visit. Transthoracic echocardiog-
raphy was performed at baseline and six, 12, and
24 months after the AF ablation. Reablation was
permitted at the investigator’s discretion without
excluding the patient from the study. All patients
were followed for a minimum of two years from
the first ablation.
Outcome Measures
The outcome measures included time to first
AF recurrence and AF burden over time. AF recur-
rence was defined as a 30-second episode of AF
when detected on Holter or continuous external
loop monitoring and an adjudicated two-minute
episode when detected by ILR. AF burden was
calculated from the ILR data as the percentage of
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time in AF between visits. All symptoms reported
via the patient activator of the ILR were compared
with simultaneously recorded rhythm strips.
The rhythm analysis was performed with
and without a three-month blanking period after
ablation. We used two AF burden cut-off limits,
0% and <0.5%, at each scheduled visit, the
latter previously suggested to classify patients as
responders versus nonresponders.13
Statistical Analysis
Categorical variables are presented as percent-
ages and continuous variables as mean± standard
deviation (SD) or median and interquartile range
(IQR), when appropriate. Boxplots were used to
visualize number of AF episodes, longest AF
episode, and AF burden between time intervals
of six months up to 24 months. For a few
missing data within these time intervals, we
used the “Last Observation Carried Forward”
method. Friedman’s test was applied to evaluate
differences between time intervals. The McNemar
test was used to evaluate differences between time
intervals for categorical variables and the paired
t-test to evaluate echocardiographic parameters.
The Mann-Whitney U-test and Wilcoxon paired
rank sum test were used to evaluate AF burden.
Time to first AF recurrence was visualized
with Kaplan-Meier curves between ILR and
intermittent monitoring and was evaluated by Cox
regression for clustered observations, which gives
hazard ratios (HR) with a 95% confidence interval
(CI) as the association measure.
Logistic regression was used to evaluate
predictors of AF recurrence detected with in-
termittent monitoring and ILR, respectively. All
variables in Table I were considered as potential
predictors but for the multiple regressions only
variables measured before ablation were included.
History of AF, AF burden, and longest AF episode
were evaluated on categorical and on a log linear
scale and left atrial diameter and body mass
index on both a linear scale and categorized as
normal weight, overweight, and obese using the
World Health Organization standard. A P value of
<0.05 was considered statistically significant. All
statistical analyses were done using SPSS version
22 (IBM Corp., Armonk, NY, USA) or STATA
release 11 (StataCorp, College Station, TX, USA).
Results
Baseline Characteristics
Fifty-nine patients were included in the
study, 57 of whom underwent AF ablation.
Following ILR implantation, one patient withdrew
and one was excluded before ablation because
of no AF documentation during symptoms.
One patient withdrew directly after the ablation
due to sepsis, one patient was excluded at
12 months because of a severe neurological
disorder, and one patient was excluded because
of cancer, from which the patient died 18 months
after ablation. Fifty-four patients completed the
24-month follow-up. The baseline characteristics
are shown in Table II. The ILR was implanted
57 ± 37 days (range 18–218 days) before the
ablation procedure. During this period, the median
AF burden was 0.9% (IQR 0–5.3). Twenty-three
(43%) patients had a reablation procedure a mean
of 11 ± 4 months after the first procedure. The
use of class IC or class III antiarrhythmic drugs
decreased significantly during the study period,
while the proportion of patients on β-blockers
and anticoagulation treatment did not change
significantly during follow-up (Fig. 1).
Rhythm Control up to 24 Months
Figure 2A shows the time to the first
recurrence of AF detected by ILR. Ninety percent
of patients with AF recurrence after the blanking
period also had a recurrence during the blanking
period compared with 15% of patients without
recurrence after the blanking period (P < 0.001).
After the blanking period, at least one AF
recurrence was detected by the ILR in 41 (76%)
patients and by intermittent follow-up in 31 (57%)
patients (Fig. 2B). All AF recurrences identified
by intermittent follow-up were also detected by
ILR. Moreover, the ILR detected AF recurrences
significantly earlier than intermittent follow-up
(hazard ratio 1.51 [95% confidence interval: 1.22–
1.87], P < 0.001). The median AF burden after
the blanking period up to the 24-month follow-
up was significantly lower when AF was only
detected by ILR (n = 10), 0.11% (IQR 0.003–
0.92), compared with when detected by both
intermittent monitoring and ILR (n = 31), 5.7%
(IQR 0.4–14.4) P = 0.001.
Thirteen (24%) patients had no AF episodes
at all detected by ILR after the end of the blanking
period and up to 24 months after ablation, while
at least one AF episode was detected by ILR in
41 (76%) patients, corresponding to a median AF
burden of 1.2% (IQR 0.3–12.3). Eleven of the 13
patients with no AF recurrence detected by ILR
had paroxysmal AF at baseline.
The proportion of patients without recurrence
of AF detected by ILR during the past six-month
period was 48% at six months, 43% at 12 months,
43% at 18 months, and 43% at 24 months, i.e.
fairly constant over time but the rhythm varied
between AF and SR among 13–19% of the patients
from one six-month period to the other, meaning
that the concordance between successive time
intervals was 81–87% (Fig. 3A). Using an AF
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Table I.
Analysis of Predictors of AF Recurrence after AF Ablation with Logistic Regression
Unadjusted AdjustedRecurrence
3–24 Months
(n = 41)
No Recurrence
3–24 Months
(n = 13) OR (95% CI) P OR (95% CI) P
Continuous Monitoring
Age, mean ± SD,
OR per year
58 ± 10 55 ± 9 1.035 (0.969–1.106) 0.31 1.076 (0.961–1.205) 0.20
Female sex 39% 38% 1.02 (0.28–3.69) 0.97 0.53 (0.10–2.91) 0.53
BMI, mean ± SD,
OR per unit
29.0 ± 5.2 29.1 ± 3.6 0.998 (0.876–1.136) 0.97 1.073 (0.899–1.208) 0.44
BMI < 25 20% 0% Reference 0.18†
BMI 25–29 39% 62% NE
BMI  30 41% 38% NE
History of AF in
months,
median (IQR),
OR per unit log
scale
72 (IQR35–120) 72 (IQR30–168) 0.65 (0.12–3.58) 0.62 0.34 (0.04–3.05) 0.34
History of AF >
72 months
46% 46% 1.01 (0.29–3.52) 0.99
AF burden before
ablation,
median (IQR),
OR per unit log
scale
1% (IQR0–9) 0% (IQR0–4) 2.15 (0.66–7.06) 0.20 2.67 (0.60–11.8) 0.20
AF burden >0.5%
before ablation
68% 46% 2.43 (0.67–8.82) 0.18
Longest AF
before ablation
in hours,
median (IQR),
OR per unit log
scale
5 (IQR0–33) 0 (IQR0–15) 2.05 (0.85–4.92) 0.11
Longest AF > 6
hours before
ablation
46% 31% 1.91 (0.50–7.33) 0.34
Persistent AF 12% 15% 0.76 (0.13–4.50) 0.77 0.25 (0.02–2.56) 0.24
Hypertension 42% 39% 1.13 (0.32-4.07) 0.85 0.76 (0.16–3.57) 0.73
LA diameter,
mean ± SD,
OR per unit
42 ± 8 41 ± 5 1.05 (0.42–2.59) 0.92 0.60 (0.16–2.29) 0.45
LA diameter <
40 mm
49% 61% 0.60 (0.17–2.13) 0.42
Early AF
recurrence <
3 months
90% 15% 50.9 (8.2–316) <0.001
Early ILR
activation <
3 months while
AF
54% 8% 13.9 (1.65–117) 0.015
(Continued)
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Table I.
Continued
Unadjusted AdjustedRecurrence
3–24 Months
(n = 31)
No Recurrence
3–24 Months
(n = 23) OR (95% CI) P OR (95% CI) P
Intermittent Monitoring
Age, mean ± SD,
OR per year
58 ± 9 55 ± 10 1.039 (0.980–1.102) 0.20 1.015 (0.926–1.112) 0.75
Female sex 32% 48% 0.52 (0.17–1.58) 0.25 0.35 (0.08–1.61) 0.18
BMI, mean ± SD,
OR per unit
28.4 ± 5.1 29.9 ± 4.4 0.933 (0.831–1.047) 0.24 0.963 (0.828–1.121) 0.63
BMI < 25 23% 4% Reference
BMI 25–29 42% 48% 0.17 (0.02–1.59) 0.12
BMI  30 36% 48% 0.14 (0.02–1.36) 0.09
History of AF in
months, median
(IQR), OR per unit
log scale
84 (36–120) 48 (24–120) 1.86 (0.43–8.06) 0.41 2.13 (0.33–13.6) 0.43
History of AF > 72
months
52% 39% 1.66 (0.56–4.96) 0.36
AF burden before
ablation, median
(IQR), OR per unit
log scale
2% (1–36) 0% (0–3) 4.06 (1.29–12.8) 0.017 4.90 (1.13–21.3) 0.034
AF burden > 0.5%
before ablation
82% 39% 6.8 (1.9–24.7) 0.003
Longest AF before
ablation in hours,
median (IQR), OR
per unit log scale
10 (3-100) 0 (0–4) 4.52 (1.66–12.3) 0.003
Longest AF >6
hours before
ablation
59% 22% 5.24 (1.50–18.3) 0.010
Persistent AF 16% 9% 2.02 (0.36–11.5) 0.43 0.59 (0.07–5.27) 0.64
Hypertension 45% 35% 1.54 (0.51–4.70) 0.44 1.63 (0.41–6.49) 0.49
LA diameter, mean
± SD, OR per unit
42 ± 8 41 ± 6 1.23 (0.56–2.70) 0.60 0.95 (0.31–2.94) 0.93
LA diameter < 40
mm
45% 52% Reference
LA diameter < 40
mm
55% 48% 1.32 (0.45–3.91) 0.61
Early recurrence < 3
months
16% 0% NE 0.06†
Early ILR activation
< 3 months while
AF
61% 17% 7.52 (2.05–27.5) 0.002
Adjusted for all variables except for longest AF before ablation, early AF recurrence and early ILR activation. Bold values are considered
statistically significant (P values < 0.05).
†Fisher exact test.
AF = atrial fibrillation; BMI = body mass index; CI = confidence interval; ILR = implanted loop recorder; IQR = interquartile range; LA =
left atrial; NE = Not estimable; OR = odds ratio; SD = standard deviation.
918 September 2016 PACE, Vol. 39
RHYTHM AND SYMPTOMS AFTER AF-ABLATION
Table II.
Baseline Patient Characteristics
n = 57
Male sex 34 (60%)
Age, years (mean ± SD) 57 ± 9
BMI (mean ± SD) 29 ± 5
Paroxysmal AF 50 (88%)
Persistent AF 7 (12%)
Months from first AF episode (median,
IQR)
57 (IQR 36–120)
Days from latest perceived AF episode 29 (IQR 3–116)
EHRA I 20 (35%)
EHRA II 23 (40%)
EHRA III 13 (23%)
EHRA IV 1 (2%)
Concomitant cardiovascular disease
Heart failure 2 (4%)
Hypertension 24 (42%)
Diabetes 2 (4%)
Coronary artery disease 1 (2%)
Previous CABG 1 (2%)
Valvular heart disease 1 (2%)
Stroke/transient ischemic attack 8 (14%)
CHADS2 scores
0 31 (54%)
1 14 (25%)
2 12 (21%)
CHA2DS2-VASc scores
0 15 (26%)
1 20 (35%)
2 22 (39%)
Echocardiogram
LVEF, % (mean ± SD) 60 ± 5
Left atrial diameter, mm (mean ±
SD)
42 ± 7
Medications
β-Blockers 37 (65%)
Class I AAD 16 (28%)
Class III AAD 16 (28%)
Warfarin 42 (74%)
Values are n (%), mean ± SD or median (IQR). AAD =
antiarrhythmic drugs; AF = atrial fibrillation; BMI = body mass
index; CABG = coronary artery bypass graft; CHADS2 =
congestive heart failure, hypertension, age 75 years, dia-
betes, prior stroke/transient ischemic attack; CHA2DS2-VASc =
congestive heart failure, hypertension, age 65 or 75 years,
diabetes, prior stroke/transient ischemic attack, vascular disease,
female sex; EHRA = European Heart Rhythm Association;
IQR= interquartile range; LVEF= left ventricular ejection fraction;
SD = standard deviation.
burden cut-off of <0.5%, 22 (41%) patients were
responders from the end of the blanking period
and up to 24 months after ablation, while AF
recurrence was confirmed in 32 (59%) patients.
During intermittent monitoring, no AF was
detected in 23 (43%) patients after ablation
(Fig. 3B). The proportion of patients without
recurrence of AF during the past six-month period
was 74% at six months, 72% at 12 months,
68% at 18 months, and 65% at 24 months,
i.e. considerably higher than with continuous
monitoring.
The number of AF episodes (P = 0.02)
(Fig. 4A) and the duration of the longest AF
episode (P= 0.04) (Fig. 4B) decreased significantly
over the two-year follow-up. The median AF
burden was <1% before the ablation and was
0.09% during the 18–24 month interval (Fig. 4C).
The seven patients with persistent AF at
baseline had a greater AF burden (P = 0.001)
and longer duration of the longest AF episode
(P = 0.01) than the 47 with paroxysmal AF before
ablation, but the groups did not differ two years
after ablation. Two patients had no AF recurrence
at all during the long follow-up, as verified by ILR,
while in four patients AF had become paroxysmal.
Meanwhile, five (11%) patients with paroxysmal
AF were in persistent/permanent AF at the end of
follow-up.
Symptoms versus Arrhythmia Recurrence
Twenty-two (54%) patients with AF recur-
rence after the blanking period also had AF when
reporting symptoms during the blanking period
as compared to one (8%) patient without AF
recurrence after the blanking period (P = 0.003).
Twenty-six patients reported symptoms using
the patient activator after the blanking period
(Table III). Twenty-one (81%) of them had AF
at least once when reporting symptoms, and five
patients (19%) had no AF recurrence during
the whole follow-up. Another three patients had
AF recurrence but no reported symptoms during
AF, but nevertheless reported symptoms at other
times. Altogether the 26 (48%) patients reported
symptoms on 341 occasions, of which 228 (67%)
correlated with AF episodes. Five of the 13
patients (38%) without AF recurrence reported
symptoms on 48 occasions after the blanking
period. Twenty-one of 41 patients (51%) with AF
recurrence reported symptoms at least once during
the follow-up.
Twenty-five patients did not use the patient
activator after the blanking period up to two years
after ablation, but 17 (68%) of them had at least
one ILR-detected AF recurrence and one patient
underwent reablation.
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Figure 1. Medications during the two-year follow-up. The change from baseline to 24 months
after ablation was statistically evaluated with the McNemar test.
Ten patients had AF recurrences after the
blanking period detected only by ILR. Five of them
indicated symptoms, three of them in connection
with AF recurrence, and two at times when they
did not have AF. The other five patients never
indicated symptoms, but one of them neverthe-
less underwent a redo procedure for recurrent
AF.
Seven of the 31 patients with AF recurrence
detected both by ILR and intermittent monitoring
never used the patient activator. The remaining
24 patients all reported symptoms and had at least
one AF episode when reporting symptoms.
Patients without symptoms were younger (P=
0.02) than symptomatic patients and more often
men (P = 0.03) (Table III). The majority of patients
without symptoms were on AADs at the ablation
(P = 0.001).
Analysis of Predictors of AF Recurrence
Eleven variables were considered as potential
predictors of AF recurrence (Table I). For continu-
ous monitoring, early recurrence (within the first
3 months) and early recurrence combined with
patient symptoms were unadjusted significantly
associated to recurrence after the blanking period.
Figure 2. Kaplan-Meier curves for freedom from atrial fibrillation after ablation showing (A) detection by the ILR at
exact times 0–24 months, and (B) a comparison between ILR and IM at scheduled visits 3–24 months, excluding the
blanking period from analysis, hazard ratio 1.51 (95% confidence interval: 1.22–1.87), P < 0.001. IM = intermittent
monitoring; ILR = implantable loop recorder.
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Figure 3. Number of patients with AF and SR measured at clinical visits after AF ablation (A) by ILR and (B) by
intermittent monitoring. No recurrence of AF = AF burden 0%. Concordance of AF or no AF = SR + SR or AF + AF
in two adjacent visits. Last observation carried forward was used for a few missing values. AF = atrial fibrillation;
ILR = implantable loop recorder; SR = sinus rhythm
AF burden and longest AF before ablation
were highly correlated, r = 0.93 (Spearman)
and only AF burden was considered in the
multiple regression together with other variables
measured at baseline. No variables were signif-
icantly associated to recurrence in the multiple
regressions.
In intermittent monitoring, early recurrence
combined with patient symptoms were unad-
justed significantly associated to recurrence after
the blanking period as well as AF burden and
longest AF before ablation. In the multiple
regression, where only baseline variables were
considered, AF burden before ablation was a
PACE, Vol. 39 September 2016 921
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A B
C
Figure 4. Boxplot showing (A) the number of AF episodes that decreased significantly over time (P = 0.02), (B)
the longest AF episode that decreased significantly over time (P = 0.04), and (C) AF burden that did not change
significantly over time. Boxplot explanation: upper horizontal line of box, 75th percentile; lower horizontal line of
box, 25th percentile; horizontal bar within box, median; the whiskers represents min and max if no outlier are present,
outliers of more than 1.5 IQR or more than three IQR from the box are labeled as circles and asterisks. AF = atrial
fibrillation.
significant predictor, odds ratio (OR) 4.90 (95%
CI: 1.13–21.3), P = 0.034. If duration of longest
AF before ablation was included instead of
AF burden, longest AF showed a significant
association in the multiple regression, OR 6.30
(95% CI: 1.84–21.5), P = 0.003.
Discussion
The main findings of our study are that the AF
burden was low after AF ablation and remained
at a very low level during the 24-month follow-
up period. Continuous rhythm monitoring was
superior to intermittent follow-up in detecting AF
recurrences, in particular in patients with a low
AF burden and/or asymptomatic AF. AF burden
>0.5% and longest AF episode >6 hours before
ablation were, separately, independent predictors
of AF recurrence detected by intermittent moni-
toring after ablation. Symptoms were reported at
least once by half of the patients using the patient
activator, but one third of these recordings did not
show AF. More than half of the patients indicating
symptoms by ILR activation confirmed to be due
to AF during the blanking period, had a later
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Table III.
Characteristics of Patients with AF Recurrence and No AF Recurrence and Symptoms Reported by Patient Activator
AF Recurrence 3–24 Months No AF Recurrence 3–24 Months
Symptoms
(n = 21)
No Symptoms†
(n = 20)
Symptoms
(n = 5)
No Symptoms
(n = 8) P*
Age, mean ± SD 60 ± 9 55 ± 10 61 ± 7 51 ± 8 0.02
Male sex 48% 75% 40% 75% 0.03
BMI < 25 19% 20% 0% 0% 0.95
BMI 25–29 43% 35% 60% 63%
BMI  30 38% 45% 40% 37%
History of AF, months 75 (IQR39–126) 54 (IQR28–115) 72 (IQR24–204) 84 (IQR36–183) 0.48
Persistent AF 9% 15% 40% 0% 0.70
HATCH score, mean ± SD 0.6 ± 0.9 0.9 ± 1 1.2 ± 1.3 0.4 ± 0.5 0.94
AF burden before ablation 2% (IQR0.3–6) 1% (IQR0–34) 5% (IQR0, 3–52) 0% (IQR0–1) 0.06
Longest AF before ablation, hours 6 (IQR2–38) 5 (IQR0–186) 15 (2–64) 0 (IQR0–0.4) 0.07
Hypertension 38% 45% 40% 38% 0.74
β-Blockers baseline 67% 70% 80% 50% 0.70
Class I or III AAD baseline 33% 80% 40% 75% 0.001
*Patients with symptoms (n = 26) versus patients without symptoms (n = 28). Bold values are considered statistically significant (P values
< 0.05).
†Three patients included with AF recurrence but no reported symptoms during AF, but symptoms at other times.
AAD = antiarrhythmic drugs; AF = atrial fibrillation; BMI = body mass index; HATCH score = hypertension, age older than 75 years,
previous transient ischemic attack or stroke, chronic obstructive pulmonary disease, heart failure; SD = standard deviation.
recurrence of AF compared to 8% of the patients
without an AF recurrence during the blanking
period.
Continuous Monitoring by ILR versus
Intermittent Monitoring
The AF detection algorithm in the Reveal R©
XT was evaluated in the XPECT trial, showing
a sensitivity of 96.1% and a negative predictive
value of 97.4% for identifying patients with any
AF compared to Holter recordings, which makes
it a suitable tool for detecting patients with
AF.9 In the present study, AF recurrences were
detected significantly earlier and more often by
ILR compared to intermittent follow-up, and one-
fourth of them were only detected by ILR. This is
in line with the ABACUS study where seven AF
recurrences were detected by intermittent moni-
toring compared to 18 by ILR.10 Several studies
have demonstrated the correlation between the
intensity of rhythm monitoring and the detection
of AF recurrence14,15 that is in favor of continuous
monitoring. Long-term intermittent monitoring is
also dependent on patient compliance, a problem
that is overcome by ILRs although it is minimally
invasive.
Most recurrences occurred early after ablation
as expected, many of them within the first three
months. If time to first recurrence of a 30 s
AF episode had been used as the only criterion
of success, the results of ablation would not
have been impressive, whether a three-month
blanking period was applied or not. However, the
median AF burden was consistently low during
the follow-up, and short-term AF recurrences
did not preclude good long-term results for the
patients. In our study, the AF burden in the 18–
24-month interval was 10% of that before ablation,
which is in line with the DISCERN AF study where
the mean daily AF burden decreased from two
hours per day to 0.3 hours per day16 in 49 patients
during a follow-up of 18 months. Thus, time to first
recurrence of AF is not an appropriate measure of
success after an intervention for AF. After ablation,
the number of AF episodes and the duration of the
longest AF episode decreased significantly during
the 24 months of follow-up.
Symptoms versus Arrhythmia Recurrence
Half of the patients in our study reported
symptoms, of which only two-thirds correlated
with AF episodes. The other half of the patients
did not report symptoms via the patient activator,
which does not reliably mean that they did not
have symptoms, supported by the fact that one
of these patients underwent reablation because
of symptomatic AF. Patients without symptoms
were younger, more often male, and were on AADs
PACE, Vol. 39 September 2016 923
BJO¨RKENHEIM, ET AL.
at ablation to a higher extent than patients with
symptoms (Table III). Pokusholov et al. found, in
a study of 129 patients ablated for paroxysmal
and persistent AF, which only 32% of reported
symptoms were due to AF.13
The main indication for AF ablation is
symptomatic AF, and reduction of symptoms is
important to the patients. However, asymptomatic
AF is common even in symptomatic patients
and its proportion increases after an ablation
procedure.3 In the DISCERN AF study using
ILRs, a previous catheter ablation of AF was the
strongest independent predictor of asymptomatic
AF. The ratio of asymptomatic to symptomatic AF
increased three times after ablation, and 12% of
patients had only asymptomatic AF recurrences
after the procedure.16 Since asymptomatic AF
carries the same risk of stroke as symptomatic AF,
proper detection of any AF is necessary for pre-
scription of subsequent adequate pharmacological
treatment.
Predictors of AF Recurrence
Eleven variables were analyzed as potential
predictors of AF recurrence (Table I). AF burden
>0.5% and longest AF >6 hours detected by
ILR before ablation, separately, were independent
predictors of AF recurrence during intermittent
monitoring. Because these two variables were
highly correlated, they could only be included
in the multiple regression analysis one at a time.
Meanwhile, the same factors were not predictors
of AF recurrence during continuous monitoring,
implying that continuous monitoring was better
than intermittent monitoring in detecting short
AF episodes and a low AF burden. Continuous
monitoring may also be useful in identifying
patients who might benefit from reablation.
Pokushalov et al. found that patients with AF
recurrences at three months after ablation who
underwent reablation had a significantly lower
rate of AF recurrences at 12 months after ablation
than patients randomized to medical therapy.17 In
our study, early recurrence was associated with
later AF recurrence in the unadjusted analysis.
Buiatti et al. also identified early recurrence as
an independent predictor of AF recurrence after
catheter ablation for lone AF in 855 patients, in
addition to smoking and first-degree AV block.18
In our study, early ILR activation while in AF
was also associated with AF recurrences in the
unadjusted analysis.
Is There a Need for Visual Validation
of Device-Detected AF?
Visually adjudicated episodes not due to AF
were not included in the adjudicated AF burden.
False-positive AF episodes, e.g. due to atrial or
in some cases ventricular premature beats during
SR, occurred during short episodes and in patients
with a low AF burden. Eventually, the difference
between the device-measured and the adjudicated
AF burden was insignificant. Hanke et al. showed
that the risk for success misinterpretation by
intermittent follow-up strategies increased in case
of low AF burden, which is consistent with our
results.19
Clinical Implications
In the present study as well as in others,10,20
ablation resulted in a very low AF burden in
most patients, and AF recurrence would have
been missed in one fourth of patients based on
intermittent follow-up. Patients should not be
regarded as free of AF unless proven during
a long and complete follow-up, and decisions
regarding anticoagulation should not be based
on intermittent rhythm analysis alone. Although
symptomatic AF is the main indication for
ablation, symptoms alone are an unreliable factor
for determination of success given the poor
correlation between reported symptoms and AF.
Also, when using continuous monitoring, the
continued indication for anticoagulants should
be based on the risk score rather than on the
remaining amount of AF. Previous reports have
yielded variable results regarding the stroke risk
and the need of anticoagulants after ablation, but
even small amounts of AF have been found to
increase the risk of stroke.7
Limitations
The number of patients was small, but they
were all followed in great detail for two years after
ablation. ILR data were downloaded at each visit
but, in occasional patients with frequent and/or
long-lasting AF recurrences, memory overflow
occurred. However, all episodes defined as AF
by the ILR appeared in the arrhythmia log,
and the durations of the missing recordings
were confirmed to be very short and contribute
minimally to the AF burden.
Conclusions
After AF ablation the AF burden was low
and remained low during the 24-month follow-
up. Nevertheless, symptoms were commonly
reported but were not a good indicator of AF
without ECG confirmation as one-thirds of patient
activated recordings did not show AF. Continuous
monitoring was superior to intermittent follow-
up in detecting especially short AF episodes and
assessing the AF burden, and one-fourth of the
patients had only device-detected AF recurrences,
which has important clinical implications for
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the selection of appropriate pharmacological
treatment during subsequent follow-up.
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